Adam Grossman - ADMA Biologics President CEO, Director
| ADMA Stock | USD 17.72 1.26 6.64% |
CEO
Mr. Adam S. Grossman is the President, Chief Executive Officer, Director and cofounder of ADMA Biologics, Inc. Mr. Grossman was a director of the Company since 2007, has served as the Companys President and Chief Executive Officer since October 2011 and as the Companys President and Chief Operating Officer between 2007 and October 2011. Mr. Grossman has over 20 years of experience in the blood and plasma industry. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman and cofounder. Mr. Grossman was chosen to serve on the Board because, as the Companys Chief Executive Officer, he is able to provide the Board with critical insight into the daytoday operations of the Company. since 2011.
| Age | 47 |
| Tenure | 13 years |
| Address | 465 State Route 17, Ramsey, NJ, United States, 07446 |
| Phone | 201 478 5552 |
| Web | https://www.admabiologics.com |
Adam Grossman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Grossman against ADMA Biologics stock is an integral part of due diligence when investing in ADMA Biologics. Adam Grossman insider activity provides valuable insight into whether ADMA Biologics is net buyers or sellers over its current business cycle. Note, ADMA Biologics insiders must abide by specific rules, including filing SEC forms every time they buy or sell ADMA Biologics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Grossman over two months ago Acquisition by Adam Grossman of 870950 shares of ADMA Biologics at 5.4 subject to Rule 16b-3 | ||
Adam Grossman over three months ago Disposition of 47396 shares by Adam Grossman of ADMA Biologics at 2.915 subject to Rule 16b-3 | ||
Adam Grossman over three months ago Disposition of 55000 shares by Adam Grossman of ADMA Biologics at 5.0 subject to Rule 16b-3 | ||
Adam Grossman over three months ago Disposition of 21752 shares by Adam Grossman of ADMA Biologics at 11.18 subject to Rule 16b-3 |
ADMA Biologics Management Efficiency
The company has return on total asset (ROA) of 0.1989 % which means that it generated a profit of $0.1989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3555 %, meaning that it created $0.3555 on every $100 dollars invested by stockholders. ADMA Biologics' management efficiency ratios could be used to measure how well ADMA Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 18, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, ADMA Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 269.9 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Found 11 records | CEO Age | ||
| Steven Lo | Vaxart Inc | 57 | |
| Eric MBA | Seres Therapeutics | 48 | |
| John MBA | Akebia Ther | 60 | |
| Steven MD | Sana Biotechnology | 54 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Jon Stonehouse | BioCryst Pharmaceuticals | 63 | |
| Dror Bashan | Protalix Biotherapeutics | 57 | |
| Pascal DVM | Atara Biotherapeutics | 61 | |
| Scott Wolchko | Fate Therapeutics | 54 | |
Management Performance
ADMA Biologics Leadership Team
Elected by the shareholders, the ADMA Biologics' board of directors comprises two types of representatives: ADMA Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ADMA. The board's role is to monitor ADMA Biologics' management team and ensure that shareholders' interests are well served. ADMA Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ADMA Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO VP | ||
| Michael Goldstein, Sr Counsel | ||
| Neal Fitzpatrick, Vice Sales | ||
| Kaitlin Kestenberg, Project Compliance | ||
| Cyndi Tolman, VP Services | ||
| Brian CPA, CFO VP | ||
| Dr DPS, CoFounder Chairman | ||
| Skyler Bloom, Senior Strategy | ||
| Brad Tade, CFO Treasurer | ||
| Cindy Petersen, Executive Resources | ||
| Adam Grossman, President CEO, Director | ||
| Drew Pantello, Vice Development | ||
| PharmD BCOP, Ex Engagement | ||
| John Hafl, Executive Sales | ||
| Michael Least, VP Operations |
ADMA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ADMA Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.51 B | ||||
| Shares Outstanding | 236.39 M | ||||
| Shares Owned By Insiders | 2.51 % | ||||
| Shares Owned By Institutions | 90.93 % | ||||
| Number Of Shares Shorted | 12.91 M | ||||
| Price To Earning | (1.55) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.